Navigation Links
MIV Therapeutics Announces Pivotal Test Results Further Validating,Company Stent Coatings Meet Critical FDA Fatigue Guidelines

ATLANTA--(BUSINESS WIRE)--Apr 5, 2007 - MIV Therapeutics Inc. (OTCBB:MIVT) (FWB:MIV), a leading developer of next-generation biocompatible coatings and advanced drug delivery systems for cardiovascular stents and other implantable medical devices, today announced that a recent Company sponsored bench test confirmed that merging Biosync Scientific's certified bare metal stent platform, which MIVT recently acquired, with the Company's polymer-free drug delivery system met critical "FDA Draft Guidance for the Submission of Research and Marketing Applications for Interventional Cardiology Devices" requirements for in vitro mechanical fatigue testing.

The milestone bench test further validates the recent acquisition of India-based Biosync Scientific. The acquisition is expected to accelerate the commercialization of MIVT's proprietary next generation stent technology that targets an estimated $8 billion marketplace.

"We want to establish a high bench mark against which similar coating will have to be compared," said Mark Landy, President of MIV Therapeutics. "This test was a major validation of both our next generation drug eluting technology as well as our strategic move to acquire Biosync Scientific. It also reflects our mission to do everything possible in our commitment to bring to the market a safe, effective product, even if it means going beyond FDA mandates."

The rigorous bench test combined Biosync's GenX Cr-Co, a highly competitive bare metal stent platform that has already received CE Mark certification, with MIVT's HAp technology, a novel polymer-free drug-eluting stent coating. The test results proved that MIVT's microporous ceramic coating demonstrated exceptional durability with no failures, exceeding critical FDA longevity requirements.

The bench test successfully demonstrated the integrity of MIV's HAp and bare metal stents under mechanical fatigue failures for a minimum of 10 y
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
4. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
5. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
6. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
7. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
8. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
9. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
10. Trophos Publishes ALS Article in Journal of Pharmacology and Experimental Therapeutics
11. Novelos Therapeutics Announces Encouraging Results in Ongoing Phase 2 Ovarian Cancer Trial at Dana-Farber/Partners Cancer Care
Post Your Comments:
(Date:8/31/2015)... , August 31, 2015 ... (TASE: BOLT, OTCQX: BLGTY) ("BioLight" or the "Company"), ... biomedical innovations in ophthalmology and cancer diagnostics, today ... (TASE: MCTC), has identified several new genetic markers ... jawbone in patients treated with bisphosphonate drugs and ...
(Date:8/31/2015)... Soligenix, Inc. (OTCQB: SNGX) (Soligenix or ... that address unmet medical needs in the areas ... has completed enrollment of the additional subjects, as ... this year, into the company,s Phase 2 study ... regulator (IDR) and is being evaluated as a ...
(Date:8/31/2015)... Calif. , Aug. 31, 2015  Asterias ... focused on the emerging field of regenerative medicine, ... dosed at Chicago -based Rush ... trial evaluating activity of escalating doses of AST-OPC1 ... sensory and motor complete cervical spinal cord injury ...
Breaking Medicine Technology:BioLight Reports Positive Clinical Study Results for Identifying New Genetic Markers to Predict Risk of Developing BRONJ 2BioLight Reports Positive Clinical Study Results for Identifying New Genetic Markers to Predict Risk of Developing BRONJ 3BioLight Reports Positive Clinical Study Results for Identifying New Genetic Markers to Predict Risk of Developing BRONJ 4Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 2Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 3Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 4Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 5Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 6Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 4Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 5Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 6
... 12, 2011  Public Relations tactics and tools are ... makes Public Relations a highly leveraged marketing investment, ... More specifically, Public Relations tools can be easily ... lifecycle, especially at launch and brand-building years. ...
...  Sigma-Aldrich Corporation (NASDAQ: SIAL ) will be presenting ... 30th Annual J.P. Morgan Healthcare Conference on Monday, January 9, ... at 4:00 PM (Pacific). Interested parties may ... Annual J.P. Morgan Healthcare Conference over the Internet available at ...
Cached Medicine Technology:Utilizing Public Relation Strategies During Pharmaceutical Lifecycle Management for Greatest Impact on Brand and Consumer Base 2
(Date:8/31/2015)... ... August 31, 2015 , ... “My mother and husband use oxygen ... Hagerhill, Ky. “I thought there could be a comfortable way to prevent the irritation, ... Cannula Ear Protector offers a more secure way to anchor the cannula tubing used ...
(Date:8/31/2015)... ... August 31, 2015 , ... ... the nation’s medical professional association for physicians and allied health professionals dedicated ... Lifestyle Medicine Foundation, announced today the establishment of the Lifestyle Medicine Lifetime ...
(Date:8/31/2015)... ... August 31, 2015 , ... Chicago-based ... with Bright Pink® to raise money and awareness for breast and ovarian health. ... Hot Pink Sassy incandescent Mood-lite sold to Bright Pink® to encourage households, dorms, ...
(Date:8/31/2015)... FL (PRWEB) , ... August 31, 2015 , ... Juvent ... their growing list of major sports figures who are finding joint pain relief after ... and former #1 men’s tennis player in the world said, “For the first time ...
(Date:8/31/2015)... MA (PRWEB) , ... August 31, 2015 , ... Now ... Dietary Guidelines advice to "make at least half your grains whole,” with the majority ... Boston-based non-profit Oldways Whole Grains Council (WGC) released these findings and others ...
Breaking Medicine News(10 mins):Health News:InventHelp® Inventor Designs Nasal Cannula Ear Protector (AVZ-1217) 2Health News:Nominations Sought for Awards Recognizing Exemplary Contribution to the Field of Lifestyle Medicine 2Health News:Nominations Sought for Awards Recognizing Exemplary Contribution to the Field of Lifestyle Medicine 3Health News:Mood-lites® is proud to launch “Brighten Our World" Campaign to Raise Money and Awareness for Breast and Ovarian Health Across America in Partnership with Bright Pink® 2Health News:Mood-lites® is proud to launch “Brighten Our World" Campaign to Raise Money and Awareness for Breast and Ovarian Health Across America in Partnership with Bright Pink® 3Health News:Mats Wilander, 7 Grand Slam Title Winner and Tennis Legend, Now Plays Without Joint Pain 2Health News:Mats Wilander, 7 Grand Slam Title Winner and Tennis Legend, Now Plays Without Joint Pain 3Health News:Most Americans Now Make Half Their Grains Whole 2Health News:Most Americans Now Make Half Their Grains Whole 3Health News:Most Americans Now Make Half Their Grains Whole 4Health News:Most Americans Now Make Half Their Grains Whole 5
... Inverness Medical Innovations, Inc. (Amex: IMA ... health management solutions, announced today that it will attend ... 12 through 15, 2009 at the Westin St. Francis ... Officer, and Jon Russell, Vice President, Finance, will attend. ...
... Ototoxicity , More cisplatin enters the inner ear ... explain why cisplatin treatment in humans can lead to ... of cisplatin a patient can tolerate is often limited ... as ototoxicity. Oxaliplatin is not frequently associated with the ...
... of,Florida,s proposed elimination of the Medicaid benefit that provides ... actually would cost,Florida millions more than the state currently ... reducing it - according to a newly released study,commissioned ... representing all of the state,s hospice providers. , ...
... adults and 19 percent of children taking chemotherapy drugs in ... or experienced other mistakes involving their medications, according to a ... of pediatrics at the University of Massachusetts Medical School, and ... Journal of Clinical Oncology . , "As cancer care continues ...
... Full recovery from an anterior cruciate ligament (ACL) reconstruction can be ... Utah published in the inaugural edition of Sports Health: A Multidisciplinary ... leg strength and lessen recovery issues. , ... Rosemont, ...
... American Scientific Resources, Inc. (Pink Sheets: ASFX), today announced the ... directors: Mr. Felix Reznick and Ms. Teresa McWilliams, American ... Boston College Law School and the New York ... Boston College Law School (J.D. 1998), and was ...
Cached Medicine News:Health News:Inverness Medical Innovations to Participate at JP Morgan Healthcare Conference on January 13, 2009 2Health News:Also in the Dec. 30 JNCI 2Health News:Also in the Dec. 30 JNCI 3Health News:Cutting Medicaid Hospice Benefit Would Cost Florida More, Put Neediest Individuals at Risk 2Health News:Cutting Medicaid Hospice Benefit Would Cost Florida More, Put Neediest Individuals at Risk 3Health News:Errors involving medications common in outpatient cancer treatment 2Health News:Adding Eccentric Resistance Training Improves Muscle Strength Following ACL Surgery 2Health News:Adding Eccentric Resistance Training Improves Muscle Strength Following ACL Surgery 3Health News:American Scientific Resources Announces Addition of New Board Members 2
... pressure sensor and continues to lead ... only sensor on the market that ... significantly improved maneuverability and pushability, it ... as well as a valuable clinical ...
... its professional AED offeringthe G3 Pro. ... ECG color display, provides manual override ... most advanced technology available to provide ... for emergency treatment of sudden cardiac ...
... The Littmann Electronic Stethoscope Model 4100WS features ... technology allowing you to reduce ambient noise ... eliminating critical body sounds. Three frequency modes ... and other body sounds: Bell (20-200 Hz), ...
... is a 3D quantitative echo system ... exams are performed. Intelligent design and ... revolutionary clinical performance and workflow. The ... data streams simultaneously and incorporates a ...
Medicine Products: